Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durability of Protection of GA2 Vaccine Against Malaria Rechallenge (CoGA-Re)
NCT06293339Phase 1Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of GA2 in malaria (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Protective efficacy at 28 days and Time to parasitaemia at 28 days. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
GA2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06293339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293339.